FibroBiologics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $7.4M | $4.5M | $2.4M | $1.1M | — |
| Operating expenses | $16.6M | $13.7M | $8.9M | $4.5M | — |
| Operating income | -$16.6M | -$13.7M | -$8.9M | -$4.5M | — |
| Interest expense | — | — | $147,000 | $654,000 | — |
| Income tax expense | $0 | $0 | $0 | $0 | — |
| Net income | -$18.6M | -$11.2M | -$16.5M | -$5.1M | — |
| Balance Sheet | |||||
| Cash and equivalents | $4.9M | $14.0M | $9.2M | $2.3M | — |
| Current assets | $6.3M | $14.2M | $9.2M | $2.6M | — |
| Total assets | $9.6M | $16.4M | $11.8M | $4.8M | — |
| Current liabilities | $1.8M | $12.7M | $9.2M | $7.1M | — |
| Total liabilities | $3.5M | $13.7M | $10.6M | $8.8M | — |
| Total debt | — | — | — | $4.3M | — |
| Stockholders' equity | $6.2M | $2.7M | $1.3M | -$4.0M | -$1.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$16.4M | -$11.9M | -$6.4M | -$4.1M | — |
| Depreciation and amortization | $244,000 | $157,000 | $47,000 | — | — |
| Stock-based compensation | $2.7M | $2.2M | $1.8M | $265,000 | — |
| Capital expenditure | $262,000 | $184,000 | $495,000 | — | — |
| Free cash flow | -$16.7M | -$12.1M | -$6.9M | — | — |
| Impairments | $0 | $0 | $0 | — | — |
Shares outstanding 5.2M · Free float 90.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.